peptide is FAQ

P21 has demonstrated efficacy in ischemic stroke recovery and traumatic brain injury models through BDNF-mediated neuroprotection and neurogenesis. Administer 50-100 μg intranasally once daily beginning 24 hours post-injury and continue for 21-28 days. Dihexa has not been extensively studied in acute brain injury contexts. Its mechanism targets synaptic enhancement rather than cellular survival pathways activated by CNTF/BDNF signaling.

Use Dihexa at 1-2 mg/kg subcutaneously daily for 7 days and schedule behavioral testing on days 5-7. The c-Met signaling pathway initiates synaptic changes within 24-48 hours, with peak effects observed in the 3-7 day window in published Morris water maze studies. P21's mechanism requires 14+ days for BDNF-mediated neurogenesis to produce measurable cognitive changes, making it unsuitable for sub-10-day timelines.

KPV tolerates oral administration because its target receptors (MC1R) are present on intestinal epithelial cells. Absorption isn't required for local gut effect. Systemic delivery after oral dosing fails due to first-pass metabolism and low bioavailability. LL-37 degrades rapidly in gastric acid and shows negligible oral bioavailability, making it unsuitable for enteral protocols. Researchers requiring systemic LL-37 exposure must use subcutaneous, intraperitoneal, or intravenous routes with dosing adjusted for the 2–4 hour plasma half-life. Encapsulation strategies (liposomes, nanoparticles) improve stability but add formulation complexity that most peptide studies cannot accommodate. If your model requires oral dosing with systemic effect, neither peptide fits. Consider alternative compounds or reformulate the research question around localized tissue endpoints.

Prioritize the peptide whose mechanism directly measures your primary endpoint. Studies focused on inflammation resolution, epithelial barrier function, or cytokine modulation should allocate budget to KPV. Substituting LL-37 for anti-inflammatory research produces weaker, less specific effects that require higher concentrations and larger sample sizes. Antimicrobial efficacy studies, wound healing models, or infection clearance protocols demand LL-37. KPV contributes nothing to pathogen burden measurements and wastes resources. Running pilot studies with both compounds to 'see what works' is the costliest approach; mechanism-first selection based on endpoint alignment prevents wasted compound and failed experiments. Our peptide portfolio allows researchers to explore high-purity research peptides matched to specific study designs rather than forcing experimental plans around available inventory.

Combination protocols using both peptides are feasible but require careful dosing sequence and endpoint measurement. Administer LL-37 first to address pathogen load, then introduce KPV 4–6 hours later to modulate the inflammatory response without interfering with initial immune cell recruitment. Studies combining antimicrobial peptides with anti-inflammatory agents show the timing window matters. Simultaneous administration can blunt LL-37's chemotactic signaling, reducing neutrophil infiltration by 30–50%. Measure inflammatory markers (TNF-α, IL-6) separately from pathogen burden (CFU counts, biofilm disruption) to isolate each peptide's contribution. This approach works in complex wound models where infection and inflammation both drive pathology.

Select P21 administered intranasally at 50-100 μg daily for 14-28 days. The peptide has been reproduced across research groups in Russia, Europe, and North America with consistent BDNF elevation and cognitive improvement in aged rodent models. Dihexa's evidence base remains concentrated within the University of Arizona research group, with only one successful independent replication published as of 2026.